Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 3, 2026
- Beam Therapeutics expects to submit risto-cel's BLA as early as year-end 2026. It ended the third quarter with $1.0 billion in cash, cash equivalents and marketable securities, with runway expected into mid-2029.
- 10-Q report · filed Nov 3, 2026
- Beam Therapeutics plans to submit a biologics license application (BLA) for risto-cel as early as year-end 2026, after completing dosing for all adult and adolescent patients in its BEACON trial.
The audio replay and transcript follow the call.